Prulifloxacin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Uncomplicated lower urinary tract infections Single dose 600 mg. Complicated lower urinary tract infections; Acute exacerbations of chronic bronchitis 600 mg/day up to 10 days.
Dosage Details
Oral
Uncomplicated lower urinary tract infections
Adult: In acute cases (simple cystits): Single dose of 600 mg.

Oral
Acute exacerbations of chronic bronchitis, Complicated lower urinary tract infections
Adult: 600 mg daily up to 10 days.
Renal Impairment
Dose adjustment is required.
Contraindications
Hypersensitivity. Pregnancy and lactation. Children or adolescents below 18 yr with uncomplicated skeletal development. History of tendon diseases related to administration of quinolones. Celiac disease.
Special Precautions
Haemolytic reactions may occur in G6PD deficiency patients. Exposure to sun or UV-ray may cause photosensitivity reactions. Lowers seizure threshold and predisposes CNS disorder patients to convulsions. Caution in patients with hypokalaemia, hypocalcaemia, or in patients who suffer from rhythm disorders. Increased risk of Achilles tendon or other tendon damage especially in elderly patients, concurrent corticosteroids-receiving patients or organ transplant recipients. Crystalluria, rhadomyolysis may occur in rare cases. Prolonged use may result in development of drug-resistant bacteria, or superinfections including Clostridium difficile-associated diarrhoea and pseudomembranous colitis. Renal impairment.
Adverse Reactions
Nausea, vomiting, epigastric pain, gastritis, diarrhoea, fever, altered taste, cephalalgia, dizziness, drowsiness, sleep disorders, ocular hyperemia, pruritis, skin rash, facial eczema, photosensitivity, muscle spasm, rhabdomyolysis, anorexia.
Potentially Fatal: Hypersensitivity, anaphylactic/anaphylactoid reactions, Stevens-Johnson syndrome.
Drug Interactions
Concurrent use with cimetidine, aluminium- and magnesium-containing antacids, or preparations containing iron and calcium reduces the absorption of Prulifloxacin. Increased concentration with probenecid. Prulifloxacin may increase serum concentration of theophylline. Quinolones may enhance hypoglycaemic effect of hypoglycaemic agents. May enhance effect of oral anticoagulants such as warfarin and its derivatives. Concurrent use of NSAIDS may increase risk of convulsions.
Lab Interference
Ingestion of food delays and reduces peak levels. Serum concentration decreases when taken with milk.
Action
Description: Prulifloxacin is the prodrug of ulifloxacin. It prevents reproduction of bacterial DNA by inhibiting DNA-gyrase in susceptible organisms.
Pharmacokinetics:
Absorption: Peak plasma concentration of Ulifloxacin was reached at 1 hr after oral administration.
Distribution: Apparent Vd: 1231 L after a single dose of prulifloxacin 600 mg. About 45% of Ulifloxacin is protein bound.
Metabolism: Extensive 1st pass metabolism to form the active metabolite, Ulifloxacin.
Excretion: Elimination half-life of Ulifloxacin: 10.6-12.1 hr. Ulifloxacin is primarily excreted unchanged by renal clearance.
Storage
Oral:
Uncomplicated lower urinary tract infections: Store below 30°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Prulifloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in